The presentation of additional data on IBSRELA at a significant conference like the Digestive Disease Week could positively impact Ardelyx's stock in the short term. It demonstrates ongoing research and development efforts and potential for increased adoption and sales of IBSRELA, especially if the new data further validates its efficacy and safety. Such events typically generate positive media coverage and can enhance investor and clinician confidence in the product and the company.